Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPOR | P19235 | 3/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1526185 | 1.00 | EPOR (0.49) | EPORFOLH1LTA4HALDH1A1ITGB3 | |
| SCHEMBL22804052 | 0.87 | EPOR (0.51) | EPORFOLH1LTA4HITGB3ITGA2B | |
| SCHEMBL3776750 | 0.87 | EPOR (0.51) | EPORFOLH1LTA4HITGB3ITGA2B | |
| SCHEMBL1491987 | 0.87 | EPOR (0.51) | EPORFOLH1LTA4HITGB3ITGA2B | |
| SCHEMBL8213619 | 0.86 | EPOR (0.50) | EPORFOLH1LTA4HITGB3ITGA2B | |
| SCHEMBL8213617 | 0.86 | EPOR (0.50) | EPORFOLH1LTA4HITGB3ITGA2B | |
| SCHEMBL12504602 | 0.85 | FOLH1 (0.54) | EPORFOLH1LTA4HALDH1A1ITGB3 | |
| SCHEMBL3222447 | 0.85 | EPOR (0.52) | EPORFOLH1LTA4HITGB3ITGA2B | |
| SCHEMBL27513666 | 0.84 | EPOR (0.54) | EPORFOLH1LTA4HALDH1A1ITGB3 | |
| SCHEMBL30417019 | 0.84 | EPOR (0.54) | EPORFOLH1LTA4HALDH1A1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4734400-A | BRONCHODILATION WITHOUT CARDIOVASCULAR SIDE EFFECTS | HOFFMANN-LA ROCHE INC. (US) | 1988-03-29 | — | — | US | disclosed |